|
|
 |
|
|
| |
|
|
|
|
 |
 |
 |
Controlled
studies show no risk.
Adequate, well-controlled
studies in pregnant
women have failed
to demonstrate risk
to the fetus.
Á¶ÀýµÈ ¿¬±¸¿¡¼ À§Ç輺ÀÌ ¾øÀ½À»
º¸¿´´Ù.
ÀӺο¡ ´ëÇÑ ÀûÀýÇϰí Àß Á¶ÀýµÈ
¿¬±¸¿¡¼, žƿ¡ ´ëÇÑ À§Ç輺ÀÌ
Áõ¸íµÇÁö ¾Ê¾Ò´Ù. |

|
No
evidence of risk in
humans. Either animal
finding show risk,
but human findings
do not; or if no adequate
human studies have
been done, animal
findings are negative.
»ç¶÷¿¡¼ À§ÇèÇÏ´Ù´Â Áõ°Å°¡ ¾ø´Ù.
µ¿¹°¿¬±¸¿¡¼´Â À§Ç輺À» º¸¿´À¸³ª
»ç¶÷¿¡¼´Â º¸ÀÌÁö ¾Ê¾Ò´Ù; ¶Ç´Â
»ç¶÷¿¡ ´ëÇÑ ÀûÀýÇÑ ¿¬±¸°¡ ½Ç½ÃµÇÁö
¾Ê¾Ò´Ù¸é, µ¿¹°¿¬±¸¿¡¼ ÅÂÀÚ¿¡ ´ëÇÑ
À§Ç輺À» º¸ÀÌÁö ¾Ê¾Ò´Ù. |

|
Risk
cannot be ruled out.
Human studies are
lacking, and animal
studies are either
positive for fetal
risk or lacking. However,
potential benefits
may justify the potential
risks.
À§Ç輺À» ¹èÁ¦ÇÒ ¼ö ¾ø´Ù.
»ç¶÷¿¡ ´ëÇÑ ¿¬±¸´Â ºÎÁ·Çϰí, µ¿¹°¿¬±¸¿¡¼´Â
ÅÂÀÚ¿¡ ´ëÇÑ À§Ç輺À» º¸À̰ųª µ¿¹°¿¡
´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÏ´Ù. ÀáÀçÀû À§Ç輺¿¡µµ
ºÒ±¸Çϰí, ¾à¹° »ç¿ë½ÃÀÇ À¯ÀͼºÀÌ
¾à¹°»ç¿ëÀ» Á¤´çÈÇÒ ¼öµµ ÀÖ´Ù. |
 |
Positive
evidence of risk.
Investigational or
post-marketing data
show risk to the fetus.
Nevertheless, potential
benefits may outweigh
the potential risks.
If needed in a life-threatening
situation or a serious
disease, the drug
may be acceptable
if safer drugs cannot
be used or are ineffective.
À§ÇèÇÏ´Ù´Â Áõ°Å°¡ ÀÖ´Ù.
ÀÓ»óÀڷᳪ ½ÃÆÇÈÄ ÀÚ·á¿¡¼ žƿ¡
´ëÇÑ À§Ç輺À» º¸ÀδÙ. ±×·³¿¡µµ
ºÒ±¸Çϰí, ¾à¹° »ç¿ëÀÇ À¯ÀͼºÀÌ
ÀáÀçÀû À§Ç輺À» »óȸÇÒ ¼ö ÀÖ´Ù.
»ý¸íÀ» À§ÇùÇÏ´Â »óȲÀ̳ª ÁßÁõ Áúȯ¿¡
»ç¿ëÀÌ ÇÊ¿äÇÑ °æ¿ì, º¸´Ù ¾ÈÀüÇÑ
¾à¹°À» »ç¿ëÇÒ ¼ö ¾ø°Å³ª º¸´Ù ¾ÈÀüÇÑ
¾à¹°ÀÌ È¿°ú°¡ ¾ø´Ù¸é »ç¿ëÇÒ ¼öµµ
ÀÖ´Ù. |

|
Contraindicated
in pregnancy. Studies
in animals or human,
or investigational
or post-marketing
reports have shown
fetal risk which clearly
outweighs any possible
benefit to the patient.
ÀÓ½ÅÁß Åõ¿©±Ý±â.
µ¿¹°À̳ª »ç¶÷¿¡ ´ëÇÑ ¿¬±¸ ¶Ç´Â
ÀÓ»ó½ÃÇèÀ̳ª ½ÃÆÇÈĺ¸°í¿¡¼ žƿ¡
´ëÇÑ À§Ç輺ÀÌ È¯ÀÚ¿¡ ´ëÇÑ ¾î¶²
À¯Àͼºº¸´Ù ¸í¹éÈ÷ »óȸÇÏ´Â °ÍÀ»
º¸¿´´Ù. * Regardless
of the designated
Pregnancy Category
or presumed safety,
no drug should
be administered
during pregnancy
unless it is clearly
needed and potential
benefits outweigh
potential hazards
to the fetus.
ÁöÁ¤µÈ Pregnancy
Category ³ª ¾ÈÀüÇÏ´Ù°í
¿©°ÜÁö´Â °Í¿¡ °ü°è¾øÀÌ,
¸í¹éÈ÷ ÇÊ¿äÇϰí &
»ç¿ë½ÃÀÇ À¯ÀͼºÀÌ Å¾ƿ¡
´ëÇÑ ÀáÀçÀû À§Ç輺À» »óȸÇÏ´Â
°æ¿ì°¡ ¾Æ´Ï¶ó¸é ¾î¶² ¾à¹°µµ
ÀÓ½ÅÁß¿¡ Åõ¿©µÇ¾î¼´Â ¾ÈµÈ´Ù. |
|
| |
 |
| |
 |
Digoxin,
Ferrous Sulfate, Folic
Acid, Levothyroxine
Sodium, Liothyronine
Sodium, Liotrix, Magnesium
Sulfate, Pyridoxine
HCl |

|
Acarbose,
Acetaminophene, Amoxicillin
& Potassium Clavulanate,
Cefaclor, Cimetidine,
Diphenhydramine HCl,
Erythromycin, Fluoxetine
HCl, Insulin, Loperamide
HCl, Metoclopramide,
Metronidazole, Orlistat |

|
Acyclovir,
Alendronate Sodium,
Aspirin, Atenolol,
Budesonide, Celecoxib,
Ciprofloxacin HCl,
Dexamethasone, Itraconazole,
Nifedipine, Ofloxacin,
Omeprazole, Prednisolone,
Salbutamol(Albuterol),
Sumatriptan Succinate |
 |
Diazepam,
Doxycycline, Enalapril
Maleate, Neomycin
Sulfate, Phenobarbital,
Propylthiouracil,
Tetracycline HCl |

|
Atorvastatin
Calcium, Ergotamine
Tartrate, Estradiol,
Estrogens conjugated,
Finasteride, Levonorgestrel,
Raloxifene HCl, Testosterone,
Warfarin Sodium |
|
| |
|
| |
|
 |
|
|
|
| |
| |
| |
|
|
|